SCHEMBL2168346

SCHEMBL2168346

CC#CCOC(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
ESR1 P03372 1/20 0.42
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
NFKB1 P19838 1/20 0.34
CYP2C19 P33261 1/20 0.34
HIF1A Q16665 1/20 0.34
GMNN O75496 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231036 0.88 ESR1 (0.43) MMP1MMP2MMP9MMP12ESR1
SCHEMBL2835108 0.84 MMP1 (0.42) MMP1MMP2MMP9MMP12ESR1
SCHEMBL2831854 0.79 MMP1 (0.43) MMP1MMP2MMP9MMP12TSHR
SCHEMBL2838655 0.79 MMP1 (0.54) MMP1MMP2MMP9MMP12CA1
SCHEMBL2833604 0.78 NPC1 (0.52) ESR1CA1CA2TSHRMAPK1
SCHEMBL2166912 0.76 CA1 (0.38) ESR1CA1CA2TSHRMAPK1
SCHEMBL22766903 0.76 ESR1 (0.41) ESR1CA1CA2TSHRMAPK1
SCHEMBL3688150 0.76 MMP1 (0.36) MMP1MMP2MMP9MMP12
SCHEMBL2834381 0.73 KMT2A (0.49) MMP1MMP2MMP9MMP12CA1
SCHEMBL196046 0.73 ESR1 (0.53) ESR1CA1CA2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348010-B1 METHOD FOR PRODUCING TETRAFLUORO COMPOUND NIPPON SODA CO (JP) 2014-02-26 EP disclosed
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
EP-2348010-A1 METHOD FOR PRODUCING TETRAFLUORO COMPOUND Nippon Soda Co., Ltd. (JP) 2011-07-27 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 MMP1 1384/4885MMP2 1012/4885MMP9 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.